tenofovir disoproxil fumarate / Generic mfg. - LARVOL DELTA

Multimodal Bone Fragility Profiling in People Living with HIV: Trabecular Bone Score, Calcaneal Quantitative Ultrasound, and Sarcopenia Screening. (PubMed, Medicina (Kaunas)) - "This study evaluated whether adding a pragmatic sarcopenia screen improves bone fragility characterization beyond DXA-BMD, trabecular bone score (TBS), calcaneal quantitative ultrasound (QUS), and biomarkers, and explored the relationship between tenofovir disoproxil fumarate (TDF) exposure and microarchitectural impairment...Viral suppression independently reduced odds of degraded TBS (aOR 0.3, 95% CI 0.1-0.9; p = 0.034). In PLWH, prolonged TDF exposure and functional impairment co-occur with worse densitometric and microarchitectural profiles; viral suppression shows an independent protective association with microarchitecture."

Biomarker • Journal • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Sarcopenia

CAN PHYSICAL EXERCISE MITIGATE TENOFOVIR-INDUCED NEPHROTOXICITY IN RATS? EXPERIMENTAL INSIGHTS (ISN-WCN 2026) - "Introduction Tenofovir Disoproxil Fumarate (TDF), a crucial antiretroviral for HIV/AIDS and hepatitis B, is a nephrotoxic drug and also induces cardiovascular dysfunction through oxidative stress and mitochondrial damage in renal tubules, leading to acute kidney injury (AKI) in 10-30% of patients...On the 29th day, the animals were euthanized under 5% isoflurane anesthesia, followed by exploratory laparotomy for blood and tissue collectionResults Results(mean±SD; *p≤0.05, t-test):Renal Function Analyzed: Neutrophil gelatinase-associated-lipocalin(NGAL), Inulin clearance (Inu), NGAL levels(ng/mL):C: (4.7±0.2),TDF:(10.3±4.1*),PT:(5.8±0.3),PT+TDF:( 6.6±1.7*).Inulin clearance (mL/min):C(0.8±0.1),TDF:(0.3 ± 0.08*),PT:(0.7 ± 0.11),PT+TDF:(0.4 ±0.09*).Oxidative Stress Markers: Increased urinary lipid peroxidation (TBARS,nM/g): C:(0.3 ± 0.08),TDF:(0.73 ± 0.2*),PT:(0.2 ± 0.05), PT +TDF:(0.22 ± 0.08)*, Reduced thiol..."

Preclinical • Acute Kidney Injury • Cardiovascular • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Nephrology • CAT • LCN2

REFRACTORY ELECTROLYTE DISORDERS IN PREGNANCY REVEALING GITTLEMAN SYNDROME (ISN-WCN 2026) - "Distinguishing GS from acquired causes (e.g., Tenofovir disoproxil fumarate (TDF)-associated proximal tubulopathy) is critical, as the diagnoses imply different maternal-fetal risks, genetic counseling considerations, and management strategies.Methods We present a unique case of a 29-year-old pregnant woman with chronic hepatitis B who was evaluated for persistent hypokalemia/hypomagnesemia initially attributed to poor intake and later to TDF use. A pattern of hypocalciuria with metabolic alkalosis and renal potassium and magnesium wasting should prompt consideration of GS and genetic confirmation. Recognizing this distinction from drug- induced proximal tubulopathy changed management in this case and supports the careful use of potassium-sparing strategies such as amiloride in pregnancy (Figure 1).Download: Download high-res image (263KB)Download: Download full-size image"

Hepatitis B • Hepatology • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • SLC2A3

KIDNEY DISEASE SCREENING AT ART INITIATION AMONG ADULTS WITH HIV IN UGANDA: A MISSED PRIORITY FOR A HIGH-RISK POPULATION (ISN-WCN 2026) - "People living with HIV (PWH) are at increased risk due to nephrotoxicity of antiretroviral therapy (ART), in part due to widespread use of tenofovir disoproxil fumarate...The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All authors report no conflict of interest.I did not use generative AI and AI-assisted technologies in the writing process."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Renal Disease

ATYPICAL IGA NEPHROPATHY UNMASKED BY IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A HIV PATIENT (ISN-WCN 2026) - "However, IRIS leading to the unmasking of glomerular diseases is rarely reported.Methods A 42-year-old woman diagnosed with HIV presented with nausea and vomiting for 2 weeks, two months after starting highly active antiretroviral therapy (HAART) containing tenofovir disoproxil fumarate (TDF) 300 mg, lamivudine 300mg, and dolutegravir 50 mg...DIF studies showed mesangial IgA (3+), C3 (1+), and kappa (3+) staining and lambda (1+).Download: Download high-res image (868KB)Download: Download full-size imageResults She was treated with IV methylprednisolone 500 mg for 3 doses, followed by oral prednisolone at 0.5 mg/kg body weight. HAART was modified to an abacavir-based regimen...To conclude, this case emphasizes the need for clinicians to be aware of the diverse renal manifestations of IRIS in the setting of HIV. It also underscores the need for vigilance after initiating HAART."

Clinical • Glomerulonephritis • Human Immunodeficiency Virus • IgA Nephropathy • Immunology • Infectious Disease • Inflammatory Arthritis • Monoclonal Gammopathy • Renal Disease • CD4

Long-term viral suppression, and cardiometabolic benefits of switch to ainuovirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study (ESCMID Global 2026) - No abstract available

Clinical • Late-breaking abstract • Human Immunodeficiency Virus • Infectious Disease

Comparative Efficacy of Entecavir and Tenofovir Disoproxil Fumarate in Preventing HBV Reactivation in Patients Receiving Biologic Diasease-Modifying Antirheumatic Drugs (APASL 2026) - No abstract available

Clinical • Hepatitis B

Risk factors for low-level viremia in Tenofovir Disoproxil Fumarate (TDF)-treated patients with chronic hepatitis B complicated by advanced hepatic fibrosis/compensated liver cirrhosis (APASL 2026) - No abstract available

Clinical • Metastases • Fibrosis • Gastroenterology • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

First Case Report of Tenofovir Disoproxil Fumarate-Induced Perichondritis: A Case Study from the Perspective of Seronegative Autoimmune Processes (APASL 2026) - No abstract available

Case report • Case study • Clinical • Immunology

Tenofovir disoproxil fumarate inhibits cholesterol absorption by downregulating the expression of duodenum NPC1L1 to reduce serum cholesterol (EASL 2026) - No abstract available

Metabolic Dysfunction-Associated Steatotic Liver Disease

Long-term efficacy and safety of tenofovir disoproxil fumarate in chronic hepatitis B: real-world experience from a North African center (EASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Efficacy and safety of tenofovir amibufenamide in patients with chronic hepatitis B: a real-world clinical study. (PubMed, Front Med (Lausanne)) - "This study enrolled 186 patients with CHB, of whom 93 received TMF and 93 received tenofovir disoproxil fumarate (TDF) for 48 weeks. In real-world clinical practice, TMF is an effective treatment for CHB. Compared with TDF, TMF is associated with superior ALT normalization and higher HBeAg seroconversion rates, along with a more favorable renal safety profile."

Journal • Real-world evidence • Hepatitis B • Infectious Disease • Inflammation

Recovery in bone mineral density following recent repeat pregnancy and breastfeeding among African women with and without HIV. (PubMed, J Bone Miner Res) - "Both WLWH-P and HIV-neg-P women showed BMD recovery to baseline for FN, LS and TH by 30-36 mo postpartum. However, mean BMD standard-scores trended lower throughout follow-up for WLWH-P compared to HIV-neg-P women. WLWH-P and WLWH-NP women had similar BMD standardized scores by 30-36 mo. The BMD recovery results are encouraging, but longer follow-up is needed to assess fracture risk among older WLWH compared to HIV-negative women."

Journal • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Diseases • Orthopedics

Neutrophil-rich Acute Interstitial Nephritis in an HIV Patient with Hidradenitis Suppurativa–Associated Systemic Inflammation (NKF-SCM 2026) - "METHODS/CASE SUMMARY A 53-year-old man with well-controlled HIV on long-term tenofovir disoproxil fumarate (TDF) presented initially with diarrhea, vomiting and slowed speech. He has been treated with doxycycline and clindamycin for severe HS...RESULTS/CASE DISCUSSION High-dose IV methylprednisolone for 3 days followed by prednisone 1 mg/kg led to rapid neurologic and renal improvement...CONCLUSION This case reflects complex interplay of HS-associated systemic inflammation, drug exposures, and tubular vulnerability, resulting in multisystem inflammation and neutrophil-predominant AIN. Recognizing HS as a potential systemic inflammatory driver may aid evaluation of similar presentations."

Clinical • Dermatology • Hidradenitis Suppurativa • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease • IL17A

Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial. (PubMed, AIDS) - P3b/4 | "Dolutegravir-based second-line regimens were associated with weight gain, which was further influenced by gender, ethnicity and HIV-related factors. DTG-based second-line regimens had no significant effect on blood pressure at 96 weeks; DTG + TDF/XTC was associated with a more favourable lipid profile than darunavir-containing regimens."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

COST-UTILITY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS ENTECAVIR FOR CHRONIC HEPATITIS B IN INDIA: A MARKOV STATE-TRANSITION MODEL (ISPOR 2026) - "From the perspective of the Indian healthcare payer, TDF provides more health benefit at a lower cost than ETV for chronic hepatitis B, making it a strong value-for-money option for routine clinical use. This evidence can inform treatment guidelines, public-sector procurement, and reimbursement decisions, ensure efficient use of healthcare resources while improving patient outcomes."

HEOR • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation

ALG-000184-202: Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-nNegative Adult Subjects with Chronic Hepatitis B (B-SUPREME) (clinicaltrialsregister.eu) - P1/2 | N=50 | Recruiting | Sponsor: Aligos Therapeutics Inc.

New P1/2 trial • Hepatitis B • Infectious Disease • Inflammation

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis B • Infectious Disease • Inflammation • Pediatrics

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Gilead Sciences | Trial primary completion date: Nov 2016 ➔ Mar 2017

Trial primary completion date • Hepatitis B • Immunology • Infectious Disease • Inflammation • Pediatrics

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Gilead Sciences | Trial primary completion date: May 2016 ➔ Nov 2016

Trial primary completion date • Hepatitis B • Immunology • Infectious Disease • Inflammation • Pediatrics

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Gilead Sciences | Trial primary completion date: Mar 2017 ➔ Jun 2017

Trial primary completion date • Hepatitis B • Immunology • Infectious Disease • Inflammation • Pediatrics

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - P3 | N=100 | Active, not recruiting | Sponsor: Gilead Sciences | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis B • Immunology • Infectious Disease • Inflammation • Pediatrics

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Gilead Sciences

New P3 trial • Hepatitis B • Infectious Disease • Inflammation • Pediatrics

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Gilead Sciences | Initiation date: Sep 2012 ➔ Dec 2012

Trial initiation date • Hepatitis B • Immunology • Infectious Disease • Inflammation • Pediatrics

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - P3 | N=90 | Active, not recruiting | Sponsor: Gilead Sciences | Trial completion date: Mar 2025 ➔ May 2030

Trial completion date • Hepatitis B • Immunology • Infectious Disease • Inflammation • Pediatrics